Alpine Immune Sciences Total Assets 2011-2026 | ALPN

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Alpine Immune Sciences

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
287 M	256 M	144 M	54.1 M	54.9 M	85.2 M	61.9 M	87.9 M	28.5 M	4.13 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
287 M	4.13 M	106 M

Quarterly Total Assets Alpine Immune Sciences

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
374 M	380 M	241 M	253 M	262 M	287 M	292 M	216 M	234 M	256 M	233 M	160 M	130 M	144 M	144 M	144 M	144 M	54.1 M	54.1 M	54.1 M	54.1 M	54.9 M	54.9 M	54.9 M	54.9 M	85.2 M	85.2 M	85.2 M	85.2 M	12.6 M	12.6 M	61.9 M	61.9 M	87.9 M	87.9 M	87.9 M	87.9 M	28.5 M	28.5 M	28.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
380 M	12.6 M	131 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	88.5 M	$ 8.52	6.57 %	$ 84.2 M	USA
BioNTech SE BNTX	22 B	$ 97.36	1.94 %	$ 27.2 B	Germany
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.57	-3.9 %	$ 8.59 B	Australia
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Amphastar Pharmaceuticals AMPH	1.63 B	$ 21.03	3.24 %	$ 983 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	377 M	$ 1.45	3.57 %	$ 373 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 2.99	2.4 %	$ 4.92 M	Israel
Aquestive Therapeutics AQST	160 M	$ 4.21	3.06 %	$ 450 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	433 M	$ 24.08	-0.56 %	$ 3.06 B	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	583 M	$ 32.41	0.51 %	$ 2.15 B	USA
Autolus Therapeutics plc AUTL	589 M	$ 1.48	-1.01 %	$ 394 M	Britain
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Cidara Therapeutics CDTX	215 M	-	-	$ 1.41 B	USA
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Brainstorm Cell Therapeutics BCLI	1.02 M	-	-2.5 %	$ 5.88 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Akari Therapeutics, Plc AKTX	47.9 M	$ 4.13	5.36 %	$ 278 B	Britain
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Esperion Therapeutics ESPR	466 M	$ 2.18	0.46 %	$ 453 M	USA
Evogene Ltd. EVGN	20 M	$ 0.78	-4.39 %	$ 27.9 M	Israel
Baudax Bio BXRX	10 M	-	0.59 %	$ 63 K	USA
Cabaletta Bio CABA	165 M	$ 3.23	3.04 %	$ 325 M	USA
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA